Sticker Shock: Ophthalmic Bevacizumab Biosimilar Could Drive Up Costs

(MedPage Today) -- SEATTLE -- Availability of a bevacizumab (Avastin) biosimilar for ophthalmic use could have the unintended consequence of driving up the cost of treating retinal disease with angiogenesis inhibitors, according to an economic...
Source: MedPage Today Public Health - Category: American Health Source Type: news